Analyses from a Centre of Short- and Long-Term Growth in Turner’s Syndrome on Standard Growth Hormone Doses Confirm Growth Prediction Algorithms and Show Normal IGF-I Levels

2012 ◽  
Vol 77 (4) ◽  
pp. 214-221 ◽  
Author(s):  
Michael B. Ranke ◽  
Roland Schweizer ◽  
David D. Martin ◽  
Stefan Ehehalt ◽  
Carl-Philipp Schwarze ◽  
...  
Author(s):  
Lucia Schena ◽  
Cristina Meazza ◽  
Sara Pagani ◽  
Valeria Paganelli ◽  
Elena Bozzola ◽  
...  

AbstractBackground:In recent years, several studies have been published showing different responses to growth hormone (GH) treatment in idiopathic short stature children. The aim of the present study was to investigate whether non-growth-hormone-deficient (non-GHD) short children could benefit from long-term GH treatment as GHD patients.Methods:We enrolled 22 prepubertal children and 22 age- and sex-matched GHD patients, with comparable height, body mass index (BMI), bone age, and insulin-like growth factor 1 (IGF-I) circulating levels. The patients were treated with recombinant human GH (rhGH) and followed until they reach adult height.Results:During GH treatment, the two groups grew in parallel, reaching the same final height-standard deviation score (SDS) and the same height gain. On the contrary, we found significantly lower IGF-I serum concentrations in non-GHD patients than in GHD ones, at the end of therapy (p=0.0055).Conclusions:In our study, the response to GH treatment in short non-GHD patients proved to be similar to that in GHD ones. However, a careful selection of short non-GHD children to be treated with GH would better justify the cost of long-term GH therapy.


2019 ◽  
Vol 31 (4) ◽  
pp. e12692 ◽  
Author(s):  
Antonio Bianchi ◽  
Antonella Giampietro ◽  
Linda Tartaglione ◽  
Sabrina Chiloiro ◽  
Raffaella Gentilella ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document